Skip to main content
Premium Trial:

Request an Annual Quote

Interpace Diagnostics Receives Approval to Launch Thyroid Test in New York

NEW YORK (GenomeWeb) – Interpace Diagnostics announced today that it has received approval from New York State to launch its ThyraMIR diagnostic assay on formalin-fixed, paraffin-embedded tissue samples from thyroid nodules.

According to Interpace, its ThyraMIR assay is now the only molecular test approved to be used on indeterminate thyroid nodule samples presented through fine needle aspirates in Asuragen's RNARetain cellular preservation device, cytology slides, and FFPE fixation in the State of New York.

Interpace's ThyraMIR panel is a microRNA gene expression classifier designed to help diagnose nodules with indeterminate cytology. In combination with New York State's previous approval of the firm's ThyGeNext platform, Interpace said that physicians and patients will have increased access to its thyroid product suite across several specimen types.

"With this increased convenience factor, we can now provide our thyroid molecular testing services to an even broader customer base," Interpace Diagnostics CEO and President Jack Stover said in a statement.

In January, Interpace signed an agreement with the University of Maryland Medical System to provide UMMS physicians with access to ThyGeNext, ThyraMIR, and PancraGen diagnostic tests.

The Scan

Study Examines Insights Gained by Adjunct Trio RNA Sequencing in Complex Pediatric Disease Cases

Researchers in AJHG explore the diagnostic utility of adding parent-child RNA-seq to genome sequencing in dozens of families with complex, undiagnosed genetic disease.

Clinical Genomic Lab Survey Looks at Workforce Needs

Investigators use a survey approach in Genetics in Medicine Open to assess technologist applications, retention, and workforce gaps at molecular genetics and clinical cytogenetics labs in the US.

Study Considers Gene Regulatory Features Available by Sequence-Based Modeling

Investigators in Genome Biology set sequence-based models against observational and perturbation assay data, finding distal enhancer models lag behind promoter predictions.

Genetic Testing Approach Explores Origins of Blastocyst Aneuploidy

Investigators in AJHG distinguish between aneuploidy events related to meiotic missegregation in haploid cells and those involving post-zygotic mitotic errors and mosaicism.